Google’s anti-aging health-tech spinoff, Calico, now has a website

It was almost a year ago that Google announced a health-tech spinoff with the ambitious goal of studying the aging process to extend human life.  The company, dubbed Calico, has been in stealth mode ever since.

But now, at least, it has a website.

The site still doesn’t say much about the company, which Google CEO Larry Page has described as one of Google’s “moon shot” efforts to have a big impact on a big problem.  But it does offer some tantalizing hints about the roster of talent that’s being assembled by Calico chief Art Levinson, who was formerly CEO at Genentech.

The list includes Hal Barron, former head of global product development and chief medical officer at biotech giant Hoffmann-La Roche, who is now Calico’s president for research and development.  Princeton geneticist David Botstein is Calico’s chief scientific officer.  Cancer researcher Robert L. Cohen is a “Calico fellow.”

And former UCSF biochemist Cynthia Kenyon – who’s described as “one of the world’s foremost authorities on the molecular biology and genetics of aging and life extension” – is Calico’s vice president for aging research.

The site doesn’t say much more, although it may eventually post job openings. Still, it offers this blurb:

“Calico is a research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Executing on this mission will require an unprecedented level of interdisciplinary effort and a long-term focus for which funding is already in place.”

(Image from Calico website)






Share this Post

  • Alan Hong

    Oh, yes. Funding is already in place – which is the most important thing.

  • Mark Nelson

    The FDA applies arbitrary definitions to “safe” and “effective”, creating a regulatory landscape unfriendly to all but the most well-funded corporations with patented non-curative treatments for ED, male pattern baldness, and other ailments. As with designer babies and 23andme’s personal genome testing, life extension will not generate the huge sales similar to treatments approved under our reimbursement-based healthcare system, so Calico will also need to shift its operation overseas in order to innovate.

  • There’s a lot more to Calico than being said – I have dealt with these aspects of this stealth company on my Linkedin post – please read and comment.